ATHE
Alterity Therapeutics Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Alterity Therapeutics Ltd
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Alterity Therapeutics Ltd
2.16
No changes.
No changes.
No peers for Alterity Therapeutics Ltd yet.
No peers for Alterity Therapeutics Ltd yet.
Annual filing, covered
20-F parsed · Aug 28 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Aug 28 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
+17.50%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Twin Lakes | $747,815 | 35.30% | 0.00% |
| Morgan Stanley | $338,660 | 15.99% | +8.02% |
| Greenleaf Trust | $332,940 | 15.72% | +93.75% |
| HB Wealth | $313,930 | 14.82% | 0.00% |
| Citadel | $201,896 | 9.53% | +87.26% |
| Manager | Value | % base | |
|---|---|---|---|
| Twin Lakes | $747,815 | 35.30% | 0.00% |
| Morgan Stanley | $338,660 | 15.99% | +8.02% |
| Greenleaf Trust | $332,940 | 15.72% | +93.75% |
| HB Wealth | $313,930 | 14.82% | 0.00% |
| Citadel | $201,896 | 9.53% | +87.26% |
—
—